摘要
目的:探讨硫酸镁联合硝苯地平对妊娠期高血压疾病患者抗氧化能力及血液流变学两方面的影响。方法:选取2010年7月～2012年5月采用硫酸镁联合硝苯地平进行治疗的33例妊娠期高血压疾病患者为研究组,然后选取同期的33例采用硫酸镁进行治疗的患者为对照组,将两组治疗前和治疗后5天的血清MDA、GSH-Px、TAC、SOD及全血黏度、全血还原黏度进行比较。结果:两组治疗前的血清MDA、GSH-Px、TAC、SOD及全血黏度、全血还原黏度比较,P值均>0.05,而治疗后5天研究组的血清MDA及全血黏度、全血还原黏度均低于对照组,血清GSH-Px、TAC及SOD均高于对照组,P值均<0.05,有统计学差异。结论:硫酸镁联合硝苯地平对于妊娠期高血压疾病患者的抗氧化能力及血液流变学指标的改善发挥着积极的作用,临床价值较高。
Objective： To explore the effect of magnesium sulphate combined with nifedipine on antioxidant capacity and hemorhe- ology of patients with hypertensive disorder complicating pregnancy （HDCP） . Methods： Thirty -three patients with HDCP who were trea- ted with magnesium sulphate combined with nifedipine from July 2010 to May 2012 were selected as study group, and 33 patients with HDCP who were treated with magnesium sulphate during the same period were selected as control group; serum levels of methane diearboxylic alde- hyde （MDA）, glutathion peroxidase （GSH -Px）, TAC, superoxide dismutase （SOD）, whole blood viscosity （WBV）, and whole blood re- duced viscosity （WBRV） before treatment and at five days after treatment in the two groups were compared. Results： There was no statisti- cally significant difference in MDA, GSH - Px, TAC, SOD, and WBV before treatment between the two groups （ P 〉 0.05 ） ; while at five days after treatment, serum levels of MDA, WBV, and WBRV in study group were statistically significantly lower than those in control group, the serum levels of GSH - Px, TAC, and SOD were statistically significantly higher than those in control group （ P 〈 0. 05 ） . Con- clusion： Magnesium sulphate combined with nifedipine plays an active role in improving antioxidant capacity and hemorheological indexes of patients with HDCP, and the clinical value is high.
出处
《中国妇幼保健》
CAS
北大核心
2013年第6期1026-1028,共3页
Maternal and Child Health Care of China
关键词
硫酸镁联合硝苯地平
妊娠期高血压疾病
MDA
GSH-PX
TAC
SOD
全血黏度
全血还原黏度
Magnesium sulphate combined with nifedipine
Hypertensive disorder complicating pregnancy
Methane dicarboxylic aldehyde
Glutathion peroxidase
TAC
Superoxide dismutase
Whole blood viscosity
Whole blood reduced viscosity
